Analyst Price Targets — LNTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 16, 2026 2:07 pm | Richard Newitter | Truist Financial | $125.00 | $103.96 | TheFly | Lantheus price target raised to $125 from $115 at Truist |
| July 15, 2026 11:25 am | Anthony Petrone | Mizuho Securities | $120.00 | $102.37 | TheFly | Lantheus price target raised to $120 from $115 at Mizuho |
| May 27, 2026 11:19 am | — | Mizuho Securities | $115.00 | $100.06 | TheFly | Lantheus price target raised to $115 from $100 at Mizuho |
| May 11, 2026 1:50 pm | — | Truist Financial | $115.00 | $94.27 | TheFly | Lantheus price target raised to $115 from $98 at Truist |
| May 7, 2026 10:26 pm | Paul Choi | Goldman Sachs | $94.00 | $91.00 | TheFly | Lantheus price target raised to $94 from $82 at Goldman Sachs |
| April 15, 2026 12:37 pm | Richard Newitter | Truist Financial | $98.00 | $82.68 | TheFly | Lantheus price target raised to $98 from $89 at Truist |
| April 13, 2026 2:42 pm | Anthony Petrone | Mizuho Securities | $95.00 | $80.50 | TheFly | Lantheus price target raised to $95 from $85 at Mizuho |
| March 17, 2026 7:08 pm | Matthew Taylor | Jefferies | $110.00 | $80.45 | StreetInsider | Lantheus Holdings (LNTH) PT Raised to $110 at Jefferies |
| February 27, 2026 5:04 pm | Richard Newitter | Truist Financial | $89.00 | $74.91 | StreetInsider | Lantheus Holdings (LNTH) PT Raised to $89 at Truist Securities |
| December 18, 2025 2:12 pm | — | Truist Financial | $82.00 | $65.35 | TheFly | Lantheus price target raised to $82 from $80 at Truist |
Latest News for LNTH
Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadership Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadership
On Friday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter to Lantheus Holdings Inc.'s (NASDAQ:LNTH) New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive neuroendocrine tumors.
The U.S. Food and Drug Administration declined to approve Lantheus Holdings' diagnostic imaging kit for types of cancer tumors, citing unresolved manufacturing-related conditions at a third-party facility, the company said on Friday.
BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA)…
Lantheus Holdings, Inc. (LNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LNTH.
U.S. House Trading
No House trades found for LNTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.